Navigation Links
Maryland Stem Cell Research Commission Recommends 62 Projects for Funding
Date:5/8/2008

COLUMBIA, Md., May 8 /PRNewswire-USNewswire/ -- The Maryland Stem Cell Research Commission (Commission) has completed its evaluation of the 122 applications in response to its three official Requests for Applications (RFAs). The board of directors of the Maryland Technology Development Corporation (TEDCO) reviewed the Commission's recommendations today and approved 62 projects for funding through the Maryland Stem Cell Research Fund (MSCRF) under the Maryland Stem Cell Research Act of 2006. This year's projects recommended for funding include:

-- 11 applications for RFA-MD-07-1 (Investigator-Initiated Research

Grants) -- These grants are designed for investigators with preliminary

data supporting the grant application.

-- 34 applications for RFA-MD-07-2 (Exploratory Research Grants) -- These

grants are designed for investigators who are new to the stem cell

field (new investigators and investigators from other fields), and for

new hypotheses, approaches, mechanisms or models that may differ from

current thinking in the stem cell field, without any preliminary data

supporting the application.

-- 17 applications for RFA-MD-07-03 (Post-Doctoral Fellowship Research

Grants) -- These new grants are for post-doctoral fellows who wish to

conduct basic and/or translational research on all types of human stem

cells in Maryland.

For a complete list of the names of the Principal Investigators, the title of each project and the institution at which the Principal Investor works, please visit http://www.mscrf.org/content/awardees/2008.cfm.

"The Commission members worked very hard to achieve a well balanced set of grant awards to cover multiple different diseases, with a variety of research approaches and the participation of many institutions throughout the state. All of the proposals considered by the Commission had already been judged to have high scientific merit, through the scientific peer review process," said Linda Powers, chairperson of the Commission. "We are excited about the potential future applications of these funded projects in diseases such as Parkinson's, ALS, brain cancer and arthritis, as well as in new enabling technologies such as non-invasive imaging, and in some fundamental biology for the prevention of teratomas or tumors."

Grants awarded from the MSCRF are contingent upon the Principal Investigator having obtained all applicable approvals from an Institutional Review Board (IRB), an Institutional Animal Care and Use Committee (IACUC), and having signed an agreement with TEDCO setting forth the scope of each project and the requirements relating to diligent execution of the project, sharing of any new cells lines, publication of results, and the like. The amounts of the awards will be disclosed once final terms are negotiated and the agreements are signed with the Principal Investigators. Research activity can then begin immediately.

The goals of the MSCRF are to broaden and advance basic knowledge of human stem cell biology that will be relevant for eventual development of clinical applications, and to enable, support and accelerate such clinical applications for prevention, diagnosis and treatment of human diseases and conditions. The Commission sought the widest range of research topics that may achieve these goals.

The work funded must be conducted in Maryland. The scientists and clinicians conducting the work must be employed or retained by an eligible Maryland-based organization while doing so. Such employment or retainer may be permanent or temporary, full-time or part-time. All Principal Investigators funded will be required to present their interim and final research results at the Maryland Stem Cell Symposium and in annual reports to the Commission.

About the Maryland Stem Cell Research Commission

Established as an independent unit within the Maryland Technology Development Corporation (TEDCO), the Maryland Stem Cell Research Commission has set up criteria, standards and requirements to administer the Maryland Stem Cell Research Fund in accordance with the Maryland Stem Cell Research Act of 2006. The Maryland Stem Cell Research Fund has been established to promote state-funded stem research. With a current $23 million budget for FY 2008, the Commission will support grants to public and private entities in the State. For more information about the Maryland Stem Cell Research Fund and a list of Commission members, please visit http://www.mscrf.org.


'/>"/>
SOURCE Maryland Stem Cell Research Commission
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
2. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
3. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
4. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
5. BioSpace Career Fair in Bethesda, Maryland Draws Hundreds of Industry Professionals
6. Hershey Center for Applied Research Supports Acceleration of Scientific Research and Development
7. Glowing zebrafish help researchers track role of sugars in the cell
8. eResearchTechnology Reports First Quarter 2008 Results
9. Roche Research Director Grace Ju Hailed as NJABR Outstanding Woman of Science
10. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
11. EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... City, Missouri (PRWEB) , ... May 27, 2016 , ... ... Development Manager, Turf and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave ... Herbicide Product Manager, where he was integral in the development and launch of many ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... state, but investors playing in this space know that volatility ... this morning,s featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... CTIC ), Lpath Inc. (NASDAQ: LPTN ), and ... now and gain access to the technical alerts for these ...
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/26/2016)... ... 26, 2016 , ... Kinder Scientific (KinderScientific.com), a leading animal ... the Company for the future. Kinder Scientific announces restructured ownership and additional ... appointed Chairman of the Board, Curtis D. Kinghorn has been appointed CEO/President and ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):